Bioxytran, Inc. (OTCMKTS:BIXT – Get Free Report) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totaling 3,141 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 193,851 shares, the short-interest ratio is currently 0.0 days.
Bioxytran Price Performance
OTCMKTS BIXT opened at $0.02 on Wednesday. Bioxytran has a 12 month low of $0.02 and a 12 month high of $0.09. The firm has a market capitalization of $2.57 million, a PE ratio of -0.75 and a beta of 2.32. The company’s 50 day simple moving average is $0.02 and its 200 day simple moving average is $0.03.
Bioxytran (OTCMKTS:BIXT – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.01) EPS for the quarter.
Bioxytran Company Profile
BioXyTran, Inc is a biotechnology company focused on developing nanotechnology-based therapeutic products. Its research has centered on methods for delivering oxygen and other therapeutic agents through the bloodstream, with the goal of addressing conditions associated with inadequate blood flow and oxygen deprivation.
The company’s lead development program has been identified as BXT-25, an oxygen-delivery product intended for potential use in ischemic conditions, including acute ischemic stroke.
See Also
- Five stocks we like better than Bioxytran
- A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?
- Could T-Mobile’s Satellite Competition Fears Create a Buying Opportunity?
- Surgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow Runway
- Tesla’s Robotaxi Lands in Paris—But Europe’s Real Fight Is Over Cheap EVs
Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with MarketBeat.com's FREE daily email newsletter.
